Short-chain fatty acid receptors involved in epithelial acetylcholine release in rat caecum

Ballout, Jasmin; Akiba, Yasutada; Kaunitz, Jonathan D.; Diener, Martin

doi:10.1016/j.ejphar.2021.174292

Cited by 5 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[96][97][98] In addition, a series of agonists of SCFA receptors can affect gut function through different mechanisms (Table 2). 66,71,[99][100][101][102] Selective GPR41 agonists are expected to become promising targets for the treatment of neurogenic diarrheal disorders because of their anti-dynamic and anti-secretory functions. 66 Selective GPR43 agonists inhibit gut transit via the PYY pathways.…”

Section: Future Perspectivesmentioning

confidence: 99%

The Role of Short Chain Fatty Acids in Irritable Bowel Syndrome

Jiang

Zhu

et al. 2022

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is characterized by abdominal pain and disordered bowel habits. The etiology of IBS is multifactorial, including abnormal gut-brain interactions, visceral hypersensitivity, altered colon motility, and psychological factors. Recent studies have shown that the intestinal microbiota and its metabolites short chain fatty acids (SCFAs) may be involved in the pathogenesis of IBS. SCFAs play an important role in the pathophysiology of IBS. We discuss the underlying mechanisms of action of SCFAs in intestinal inflammation and immunity, intestinal barrier integrity, motility, and the microbiota-gutbrain axis. Limited to previous studies, further studies are required to investigate the mechanisms of action of SCFAs in IBS and provide more precise therapeutic strategies for IBS.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

The Role of Short Chain Fatty Acids in Irritable Bowel Syndrome

Jiang

Zhu

et al. 2022

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…Some bacterial groups can produce valuable metabolites, including short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate [14]. The SCFAs may provide energy to intestinal epithelial cells [15]. Additionally, SCFAs also perform important functions in immune cells, such as maintaining homeostasis and/or the health of the host [16].…”

Section: Introductionmentioning

confidence: 99%

Gut Microbiota Potentiates the Effect of Immune Checkpoint Therapy against Cancers

Sawamura¹,

Taniguchi²,

Ikeda³

et al. 2021

RPN

View full text Add to dashboard Cite

Immune checkpoints have been aggressively investigated for anti-cancer immunotherapy. The power of microbiota on the outcome of this immunotherapy has attracted much attention. For example, intestinal microorganisms play a key role in the effectiveness of programmed cell death 1 (PD1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade. Additionally, short-chain fatty acids produced in the gut may modulate anti-CTLA4 and anti-PD1 stimulated immune responses and their anti-tumor efficacy. Enhancing the anti-tumor effects of CTLA4 blockade depends on specific Bacteroides sp. of the gut microbiota, suggesting novel approaches to improve such immunotherapies. However, the molecular mechanism of the immune-potentiation remains largely unknown. Changes in the microbiota are influenced by dietary and environmental factors. Here, we have suggested the molecular mechanism of action regarding the interplay between gut microbiota and the anti-cancer immune system with APRO family proteins, which might contribute to innovative cancer therapy in the future.

show abstract